FindMyKOL
Clinical trialNCT03448068CompletedPhase 2Interventional

Perioperative Ketamine for Pain With Gastric Bypass

NCT03448068 is a phase 2 interventional trial sponsored by Mayo Clinic. As of 18 Nov 2026, it is completed. It studies Ketamine and Standard Therapy in Ketamine and Laparoscopic Gastric Bypass Surgery. The registry lists an enrollment of 34 participants at 1 site in 1 country. The registry lists a start date of 16 Apr 2018 and a primary completion date of 9 Jan 2020.

SponsorMayo Clinic →Enrollment34KetamineLaparoscopic Gastric Bypass Surgery
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03448068
FieldValue
Registry IDNCT03448068
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorMayo Clinic
Enrollment34
Registered sites1
Countries1
ConditionsKetamine and Laparoscopic Gastric Bypass Surgery
DrugsKetamine and Standard Therapy
Start16 Apr 2018
Primary completion9 Jan 2020
Study completion9 Jan 2020
Last update posted29 Apr 2021

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Opioid medications such as morphine, hydrocodone and oxycodone are standard for treating pain after surgery, however there are disadvantages. Because of the way opioids work, gastric bypass patients may have an increased risk of having sedation or problems with breathing. In patients with sleep apnea, opioids may increase the risk of severe apnea. Ketamine is an alternative pain medicine that can be used to treat pain after surgery and may have fewer effects on breathing. Using ketamine as part of the regimen may be a better choice for laparoscopic gastric bypass patients. This study is being done to find out if intraoperative ketamine infusion combined with continuation for twenty-four hours post-surgery provides superior pain control and decreases post-operative opioid use versus standard non-ketamine therapy.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Arizona, United States1 site
  • Mayo Clinic in Arizona

    Phoenix

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizona: 1 siteAZ1UtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

KetamineStandard Therapy
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03448068

Each answer restates registry values shown on this page.

What is NCT03448068?

NCT03448068 is a phase 2 interventional trial sponsored by Mayo Clinic. It studies Ketamine and Standard Therapy in Ketamine and Laparoscopic Gastric Bypass Surgery.

Who leads NCT03448068?

The registry names Andrew W Gorlin, M.D. (principal investigator, Mayo Clinic) as the overall official.

Where does NCT03448068 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03448068 study?

The registered drug and biological interventions are Ketamine and Standard Therapy.

When did NCT03448068 end?

The registry lists a primary completion date of 9 Jan 2020 and a study completion date of 9 Jan 2020. The sponsor last updated the record on 29 Apr 2021.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.